Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fluticasone propionate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Placebo |
| 2 | ACTIVE_COMPARATOR | Fluticasone 440 mcg |
| 3 | ACTIVE_COMPARATOR | Fluticasone 1980 mcg |
| Name | Type | Description |
|---|---|---|
| fluticasone propionate | DRUG | Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods |
| Comparator: Placebo to fluticasone | DRUG | Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods |
| Comparator: Lipopolysaccharide (LPS) | DRUG | 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods |
| Comparator: albuterol | DRUG | Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit. |
Inclusion Criteria: * Female subjects who can have children must have a negative pregnancy test at screening and agree to use two methods of birth control throughout the study * Male subjects with female partner(s) who can have children agree to use an acceptable method of birth control throughout ...
Fluticasone propionate is a small molecule being studied for airway inflammation in the respiratory therapeutic area. It is currently in Phase 1 clinical development as an investigational therapy. The drug is being evaluated for its effects on biomarkers of airway inflammation.
Fluticasone propionate is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this small molecule for the treatment of airway inflammation.
Fluticasone propionate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed to evaluate the drug in healthy volunteers.
Fluticasone propionate has one completed clinical trial, NCT00869596, titled "Study of Biomarkers of Airway Inflammation (0000-128)." This Phase 1 study enrolled 22 participants, was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.
Fluticasone propionate is a small molecule being investigated for its effects on airway inflammation. The specific molecular target has not been disclosed in available information, so its mechanism of action is not fully characterized in public data.